Hypertension isdefined bysustained bloodpressure above____ mmHg.Follistatintreatment induces______ of PVAT, aphenotypeassociated withimproved vascularfunction.FST lowersROS levels, asindicated by adecrease in______ levels.Our assaydirectlymeasureshydrogen______ levels.FST wasadministeredevery______ day.Follistatinincreases theexpression of______, which iscritical for nitricoxide production.Neutralizingantibodiestargetedactivin A and______.Whichnormotensivestrain served asour control?_____________The fluorescentproductproduced in theAmplexRedassay is called______.Follistatintreatmentreduced bloodpressure byapproximately______ mmHg.What assay didwe use toquantifyhydrogenperoxide?_____________Which type of assayis used to evaluateNO levels in ourstudy: fluorometricor colorimetric? _____________What is theendogenousprotein we studiedthat antagonizesactivin?_____________Follistatinmust maintainits proper______ to befunctional.What does theabbreviation'SHR' stand for? _____________Our study showsthat blockingactivin signalingreduces ______production.Follistatinretains itsantioxidanteffect evenwhen denatured.True/FalseFST’santioxidanteffect is lostif it is______.Whichhypertensiveanimal modeldid we use?___________Enhanced NObioavailabilityindicatesimproved______."In our experiments,the reduction inoxidative stress wasmeasured as adecrease in the foldchange of ______.Which proteinmarker indicatesa brown adiposephenotype inPVAT?_____________In our study,follistatin wasadministered toSHRs over aperiod of______ weeks.Follistatin isknown toneutralizesignaling by______.Hypertension isdefined bysustained bloodpressure above____ mmHg.Follistatintreatment induces______ of PVAT, aphenotypeassociated withimproved vascularfunction.FST lowersROS levels, asindicated by adecrease in______ levels.Our assaydirectlymeasureshydrogen______ levels.FST wasadministeredevery______ day.Follistatinincreases theexpression of______, which iscritical for nitricoxide production.Neutralizingantibodiestargetedactivin A and______.Whichnormotensivestrain served asour control?_____________The fluorescentproductproduced in theAmplexRedassay is called______.Follistatintreatmentreduced bloodpressure byapproximately______ mmHg.What assay didwe use toquantifyhydrogenperoxide?_____________Which type of assayis used to evaluateNO levels in ourstudy: fluorometricor colorimetric? _____________What is theendogenousprotein we studiedthat antagonizesactivin?_____________Follistatinmust maintainits proper______ to befunctional.What does theabbreviation'SHR' stand for? _____________Our study showsthat blockingactivin signalingreduces ______production.Follistatinretains itsantioxidanteffect evenwhen denatured.True/FalseFST’santioxidanteffect is lostif it is______.Whichhypertensiveanimal modeldid we use?___________Enhanced NObioavailabilityindicatesimproved______."In our experiments,the reduction inoxidative stress wasmeasured as adecrease in the foldchange of ______.Which proteinmarker indicatesa brown adiposephenotype inPVAT?_____________In our study,follistatin wasadministered toSHRs over aperiod of______ weeks.Follistatin isknown toneutralizesignaling by______.

Follistatin to the Rescue: Bingo for Lowering Pressure and Defeating ROS - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. Hypertension is defined by sustained blood pressure above ____ mmHg.
  2. Follistatin treatment induces ______ of PVAT, a phenotype associated with improved vascular function.
  3. FST lowers ROS levels, as indicated by a decrease in ______ levels.
  4. Our assay directly measures hydrogen ______ levels.
  5. FST was administered every ______ day.
  6. Follistatin increases the expression of ______, which is critical for nitric oxide production.
  7. Neutralizing antibodies targeted activin A and ______.
  8. Which normotensive strain served as our control? _____________
  9. The fluorescent product produced in the AmplexRed assay is called ______.
  10. Follistatin treatment reduced blood pressure by approximately ______ mmHg.
  11. What assay did we use to quantify hydrogen peroxide? _____________
  12. Which type of assay is used to evaluate NO levels in our study: fluorometric or colorimetric? _____________
  13. What is the endogenous protein we studied that antagonizes activin? _____________
  14. Follistatin must maintain its proper ______ to be functional.
  15. What does the abbreviation 'SHR' stand for? _____________
  16. Our study shows that blocking activin signaling reduces ______ production.
  17. Follistatin retains its antioxidant effect even when denatured. True/False
  18. FST’s antioxidant effect is lost if it is ______.
  19. Which hypertensive animal model did we use? ___________
  20. Enhanced NO bioavailability indicates improved ______.
  21. "In our experiments, the reduction in oxidative stress was measured as a decrease in the fold change of ______.
  22. Which protein marker indicates a brown adipose phenotype in PVAT? _____________
  23. In our study, follistatin was administered to SHRs over a period of ______ weeks.
  24. Follistatin is known to neutralize signaling by ______.